Merck KGaA names new head of biosimilars unit
This article was originally published in Scrip
Darmstadt, Germany-headquartered Merck KGaA has named Boehringer Ingelheim's former head of biopharmaceuticals, Simon Sturge, head of its biosimilars unit – effective 1 March 2014. Mr Sturge will be based at the unit in Canton de Vaud, Switzerland and will report to Stefan Oschmann, a member of Merck's executive board responsible for the company's pharmaceutical businesses. Prior to Boehringer Ingelheim Mr Sturge was CEO of Dutch biotech-company OctoPlus.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.